Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, Morrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG. Rowinsky EK, et al. Among authors: aylesworth c. J Clin Oncol. 2000 Jan;18(1):178-86. doi: 10.1200/JCO.2000.18.1.178. J Clin Oncol. 2000. PMID: 10623708 Clinical Trial.
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Villalona-Calero MA, et al. Among authors: aylesworth c. J Clin Oncol. 1998 Aug;16(8):2770-9. doi: 10.1200/JCO.1998.16.8.2770. J Clin Oncol. 1998. PMID: 9704730 Clinical Trial.
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD. Rowinsky EK, et al. Among authors: aylesworth c. J Clin Oncol. 1998 Sep;16(9):2964-76. doi: 10.1200/JCO.1998.16.9.2964. J Clin Oncol. 1998. PMID: 9738565 Clinical Trial.
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J Jr, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen DS, Skillings J, Rowinsky EK. Hidalgo M, et al. Among authors: aylesworth c. J Clin Oncol. 2001 May 1;19(9):2493-503. doi: 10.1200/JCO.2001.19.9.2493. J Clin Oncol. 2001. PMID: 11331328 Clinical Trial.
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burris HA 3rd, Eckhardt SG, Stephens CD, Forral K, Nicol SJ, Von Hoff DD. Rothenberg ML, et al. Among authors: aylesworth c. Ann Oncol. 1998 Jul;9(7):733-8. doi: 10.1023/a:1008286908930. Ann Oncol. 1998. PMID: 9739439 Free article. Clinical Trial.
39 results